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Background: Calcitonin gene-related peptide (CGRP) and nitric oxide (NO) are regarded as key mediators in mi-
graine and other primary headaches. Migraineurs respond to infusion of nitroglycerin with delayed headaches, and
inhibition of CGRP receptors has been shown to be effective in migraine therapy. In animal experiments nitrovaso-
dilators like nitroglycerin induced increases in spinal trigeminal activity, which were reversed after inhibition of CGRP
receptors. In the present study we asked if CGRP receptor inhibition can also prevent spinal trigeminal activity in-
duced by nitroglycerin.
Methods: In isoflurane anaesthetised rats extracellular recordings were made from neurons in the spinal trigeminal
nucleus with meningeal afferent input. The non-peptide CGRP receptor inhibitor MK-8825 (5 mg/kg) dissolved in
acidic saline (pH 3.3) was slowly infused into rats one hour prior to prolonged glyceryl trinitrate (nitroglycerin) infu-
sion (250 μg/kg/h for two hours).
Results: After infusion of MK-8825 the activity of spinal trigeminal neurons with meningeal afferent input did not
increase under continuous nitroglycerin infusion but decreased two hours later below baseline. In contrast, vehicle
infusion followed by nitroglycerin was accompanied by a transient increase in activity.
Conclusions: CGRP receptors may be important in an early phase of nitroglycerin-induced central trigeminal activ-
ity. This finding may be relevant for nitroglycerin-induced headaches.
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MigraineBackground
Calcitonin gene-related peptide (CGRP) and nitric oxide
(NO) are regarded as key mediators in the generation of
migraine and other primary headaches [1,2], based on
several clinical data. CGRP has been found at elevated
concentrations in jugular venous blood and saliva during
attacks of migraine and cluster headache attacks [3–5],
though this finding is not without contradiction [6].
Infusion of low doses of CGRP caused delayed migraine-
like headaches in a group of migraineurs different to
healthy control persons [7], possibly indicating a special
sensitivity for this neuropeptide associated with migraine
predisposition. Furthermore, migraine and cluster headache* Correspondence: messlinger@physiologie1.uni-erlangen.de
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Erlangen-Nürnberg, Universitätsstr 17, 91054 Erlangen, Germany
© 2013 Feistel et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pattacks can be treated with triptans, which is paralleled by
normalisation of CGRP levels [3,8], or by CGRP receptor
inhibitors like olcegepant (BIBN 4096BS) and telcagepant
(MK-0974) [9–11]. Likewise, nitrovasodilators such as
nitroglycerin can induce delayed migraine-like headaches in
migraineurs [12] and other types of headaches in primary
headache patients [13,14]. Blockade of the endogenous NO
generation with an unspecific NO synthase inhibitor was
successful in alleviating migraine pain [15], while selective
inhibitors of the inducible NO synthase seemed to be inef-
fective in reducing or preventing migraine pain [16,17].
From these clinical data it can be concluded that endogen-
ous CGRP and NO, most likely produced from neuronal or
endothelial NO synthases, may play a role in the generation
of migraine pain and other primary headaches.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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demonstrating the involvement of CGRP and NO in
meningeal nociception, which is assumed to underlie the
generation of headaches. Particularly, electrophysio-
logical recordings in the rat spinal trigeminal nucleus
caudalis from neurons that receive afferent input from
meningeal tissues provide a reliable integrative measure
of trigeminal activity. Infusion of the nitrovasodilators
sodium nitroprusside (SNP) and nitroglycerin (glyceryl
trinitrate, GTN) induced ongoing activity of spinal
trigeminal neurons with meningeal afferent input [18],
resembling the clinical experiments in migraineurs. The
increase in activity started after 20–40 min and plat-
eaued after 1–2 hours. Conversely, L-NAME, a non-
specific inhibitor of endogenous NO production, re-
duced the pre-existing spontaneous activity to about the
half [19]. Similarly, the CGRP receptor antagonist olce-
gepant (BIBN4096BS) applied intravenously decreased
both spontaneous and heat-evoked spinal trigeminal
activity in a dose-dependent manner [20]. Importantly,
the activity evoked by SNP and nitroglycerin was also
decreased after CGRP receptor blockade to the pre-
existing level, suggesting an interaction of CGRP and
NO mechanisms in neuronal activity evoked by nitrova-
sodilators [18].
In the present study we have used MK-8825, a new
potent inhibitor for rat CGRP receptors, which showed
concentration-dependent inhibition of capsaicin-evoked
dermal blood flow with an EC50 of about 7.4 μM [21].
MK-8825 is structurally related to the CGRP receptor
inhibitor MK-3207, which proved to be effective in the
acute treatment of migraine [9,11].
The rationale for the present study was to examine if
CGRP receptor blockade by MK-8825 can prevent the
increase in neuronal activity induced by nitroglycerin
using the aforementioned model of spinal trigeminal re-
cordings. Answering this question may reveal if CGRP
receptors are involved in the nitroglycerin-induced
promotion of neuronal activity and may have clinical
relevance regarding the time of intervention with a




The study was performed in accordance with the ethical
guidelines of the International Association for the Study
of Pain and the German laws for animal protection
and treatment of laboratory animals. The protocol was
reviewed by an ethics committee and authorised by the
local district government.
Twenty-eight adult male Wistar rats, bred and held in
the Institute’s own animal house, with body weights ran-
ging from 250 to 410 g were used. Rats were initiallyanaesthetised by breathing 4% isoflurane (Forene, Abbott,
Wiesbaden, Germany) using an evaporator system (Vapor
19.3, Dräger, Lübeck, Germany). After quick insertion of a
tracheal tube they were artificially ventilated (Rodent
Ventilator, Ugo Basile, Comerio VA, Italy) with 2% isoflur-
ane in oxygen-enriched room air. Catheters were intro-
duced into the right femoral artery and vein to record
systemic blood pressure and to administrate substances.
The arterial catheter was permanently perfused with saline
(rate 0.2 ml/h) supplemented with 1 IU/ml heparin
(Heparin-Natrium-5000-ratiopharm, Ulm, Germany). End-
expiratory CO2 was monitored (Artema MM 200, Karl
Heyer, Bad Ems, Germany) and held at 3% by modulating
the ventilation frequency between 70 and 100 strokes per
minute, which suppressed spontaneous breathing. Body
temperature was measured by a rectal probe and main-
tained at 37–37.5°C by a feedback controlled heating
pad (TKM 0902, Föhr Medical Instruments, Frankfurt,
Germany). Arterial pressure was between 70 and
100 mmHg (Pressure Monitor BP-1, World Precision
Instruments, Sarasota, Florida). The vital parameters
were recorded during the whole experiment. The depth
of narcosis during the experiment was constant, so that
noxious pinch stimuli did not evoke nociceptive re-
flexes or changes in arterial blood pressure. At the end
of the experiment the animals were euthanised by
intravenous injection of an overdose of thiopental
(Trapanal, Nycomed, Konstanz, Germany).
Specific surgery
The animals were transferred to a stereotaxic frame to
hold the head in a fixed horizontal position using ear
bars and a snout clamp. The skin was cut along the mid-
line from the bregma to the lamda and the skin flaps
were retracted laterally. The right parietal bone was
carefully trepanised under liquid cooling using a dental
drill to expose the dura mater in the cranial window.
Care was taken to keep the dura mater intact and to
avoid bleeding from dural blood vessels. The dura was
protected from drying with 0.9% saline during the ex-
periment. The neck muscles were detached from their
insertions, separated in the midline and held apart with
a clamp. The medullary brainstem was made accessible
by cutting the atlanto-occipital ligament and the spinal
dura underneath.
Recordings
For extracellular recordings of signals a custom-made
carbon fibre glass electrode was inserted into the spinal
trigeminal nucleus caudalis of the ipsilateral medulla.
Using a microstepper, the electrode was moved through
the brainstem at steps of 2.5 μm. Single units with men-
ingeal receptive fields were detected by their firing of
action-potentials in response to mechanical probing of
Figure 1 Histograms showing typical patterns of neuronal
activity. Unit from the sample treated with MK-8825 (a) and from
the vehicle group (b). Vehicle or MK-8825 (5 mg/kg) was slowly i.v.
infused between 30 and 40 min, followed by a continuous infusion
of nitroglycerin (GTN, 250 μg/kg/h) 60 min later.
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and processed (CED 1401, Cambridge Electronic Design,
Cambridge, UK). Spike-analysis was done offline using
the discharges generated by mechanical stimulation of
meningeal receptive fields as a template (Spike 2 soft-
ware application, Cambridge Electronic Design).
At the end of the experiments the recording position
relative to the obex was assessed by a two-dimensional
micrometer system. In some experiments an electric
lesion was made by anodal current passed through the
recording electrode, and after thiopental injection the
animal was perfused in deep anaesthesia through the left
ventricle with saline followed by paraformaldehyde solu-
tion (4%) for fixation. The brainstem was dissected and
histologically processed to localise the recording site.
Experimental protocols
When the neuronal activity of a unit was visibly stable,
its baseline was recorded for a period of 30 min without
any treatment. In 12 experiments the CGRP receptor an-
tagonist MK-8825 (5 mg/kg) dissolved in saline (1 ml/kg
body weight, pH 3.3) was i.v. infused at a constant rate
within a period of 10 minutes and the recording was
continued for further 50 minutes (see Figure 1). In 11
control experiments vehicle (buffered saline, pH 3.3) was
infused instead of MK-8825, which was a possible con-
founding factor. Stimulation with acidic solutions can
cause sensitisation of spinal trigeminal neurons with re-
ceptive fields in the rodent cranial dura mater [22]. The
infusion of MK-8825 or vehicle was followed by a con-
tinuous infusion of nitroglycerin (GTN, 250 μg/kg/h)
over a period of 120 min. The infusion rate of nitrogly-
cerin was low enough to avoid lowering of systemic
blood pressure by more than 5 mmHg, as figured out in
previous experiments [18]. In six additional experiments
nitroglycerin was infused at the same rate without pre-
administration of MK-8825 or vehicle.
Chemicals
CGRP receptor antagonist MK-8825 (courtesy of the
Merck & Co. Inc., NJ, USA) was dissolved in acidic
saline (pH 3.3) and i.v. injected at a concentration
of 5 mg/kg within 10 minutes. Acidic saline of pH 3.3
was used as vehicle instead of MK-8825. Nitroglycerin
(Trinitrosan, Merck Serono, 250 μg/kg/h) was dissolved
in 1 ml isotonic saline for i.v. infusion.
Data analysis and statistics
Statistical tests were performed using Statistica 7.0 soft-
ware (StatSoft, Tulsa, OK, USA). In the sample of exper-
iments combining MK-8825/vehicle with nitroglycerin
(N = 12/11) the course of activity was analysed by one-
and two-way ANOVA with repeated measurements
followed by Fisher’s least significant difference (LSD)post hoc test using regular intervals of 10 and 30 min.
The Wilcoxon matched pairs test was used to compare
the neuronal activity within periods of 30 min in the
group of units treated only with nitroglycerin (N = 6,
normal distribution not verifiable). Differences were
considered significant at P < 0.05. For the diagrams the
activity was normalised to the mean baseline activity.
Results
General properties of neurons
Twenty-nine units recorded in 28 experiments were in-
cluded in this study. The recording sites were located
1.3 - 3.25 mm caudal to the obex, 0.35 – 1.75 lateral to
the midline and at depths of 386 – 1302 μm below the
dorsal surface of the medulla. The ongoing activity of
these units during the baseline period of 30 min ranged
from 7 to 1685 (mean 481) spikes per minute. The men-
ingeal receptive fields of the units were mostly located
close to the middle meningeal artery. The mechanical
threshold, determined with graded von Frey filaments in
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from 0.78 to 11.8 mN. The units were activated by elec-
trical square pulses (duration 1 ms) applied to the men-
ingeal receptive fields, thresholds were ranging from 0.4
to 2.4 mA. The latencies after a single electrical pulse
close above threshold ranged from 12 to 60 ms. With an
assumed conduction distance of 25 mm from the stimu-
lation site to the caudal medulla the recorded units were
concluded to be driven by slowly conducting Aδ and/or
C-fibres from the dura mater. All units received conver-
gent input from facial areas in the ophthalmic, maxillary
or mandibular division of the trigeminal nerve as well as
from the temporal muscle or the neck muscles and the
periosteum around the cranial window.
Neuronal responses to MK-8825 followed by nitroglycerin
After recording of baseline activity the infusion of MK-
8825 (5 mg/kg) was not accompanied by significant
changes in activity (Figure 1a), though there was a slight
tendency towards a transient increase in the whole sam-
ple (see Figure 2a-b). After one hour during the subse-
quent continuous infusion of nitroglycerin (250 μg/kg/h)
the activity decreased below baseline levels in the whole
sample of units (N = 12, ANOVA, F20,220 = 2.90, P <
0.001). Finally the activity within all 10 min periods dur-
ing the last 50 min was significantly lower compared to
all 10 min periods before infusion of nitroglycerin (LSD
test, P < 0.05 each; Figure 2a). Comparing periods of
30 min between the MK-8825 and the vehicle sample,
two-way ANOVA with repeated measurements indicated
a difference in time course (F6,120 = 2.73, P < 0.02), which
was due to a significant decrease in activity within the
last 90 min of the MK-8825 group compared to baseline
and to the period of MK-8825 infusion (LSD test, P <
0.05 each; Figure 2b).
Neuronal responses to vehicle followed by nitroglycerin
The activity of units varied considerably following
infusion of vehicle (saline pH 3.3) and nitroglycerin
(Figure 1b). Repeated measures ANOVA indicated a sig-
nificant change in activity during the recording time
(N = 11, ANOVA, F20,200 = 1.96, P = 0.01). During the in-
fusion of vehicle there was a tendency towards an in-
crease in the whole sample without reaching significance
(see Figure 2a-b). The subsequent infusion of nitrogly-
cerin was accompanied by a significant increase in activ-
ity (Figure 1b) which in the whole sample of units was
significant within the first 20 min and the period of 30–
40 min after onset of the nitroglycerin infusion com-
pared to the baseline (LSD test, P < 0.05 each; Figure 2a).
In the second hour of nitroglycerin infusion the activity
declined. Two-way ANOVA with repeated measure-
ments for analysis of 30 min periods in the MK-8825
and the vehicle sample showed that the activity waslowered within the last 30 min of the vehicle group com-
pared to the period of nitroglycerin infusion. (LSD test,
P < 0.05; Figure 2b).
Neuronal response to nitroglycerin alone
To re-examine the apparent decrease in activity within
the second hour of nitroglycerin infusion, we applied
nitroglycerin without any other treatment for two hours
in six additional experiments. The activity increased sig-
nificantly during the second 30 min period after onset of
the nitroglycerin infusion (Wilcoxon matched pairs test,
p < 0.05) but during the second hour of nitroglycerin in-
fusion it returned to control levels (Figure 2c).
In none of the experiments systemic parameters chan-
ged significantly during the infusions.
Discussion
In the present study we performed extracellular record-
ings in the caudal spinal trigeminal nucleus from neu-
rons with receptive fields in the cranial dura mater. The
activity of these neurons is a good integrative measure of
meningeal nociception and is assumed to correlate with
headaches in humans [23,24]. Previous experiments have
shown that in most of these neurons intravenous infu-
sion of nitrovasodilators like sodium nitroprusside or
nitroglycerin induced a delayed or continuous increase
in activity, which was reduced to baseline after infusion
of the CGRP receptor antagonist olcegepant [18,23]. The
main purpose of the present study was to examine if in-
hibition of CGRP receptors with the new CGRP receptor
antagonist MK-8825 is also able to prevent an increase
in neuronal activity induced by nitroglycerin.
Study design and effects of nitroglycerin
We have used a continuous low-dose infusion of nitro-
glycerin to avoid significant lowering of the blood pres-
sure that could occur at higher doses. Since MK-8825
must be dissolved in acidic saline (pH 3.3), the vehicle
was titrated to the same pH. The infusion of these acidic
solutions was followed by a trend towards an increase in
activity in several units without reaching statistical sig-
nificance in the whole sample of experiments. We as-
sume that the acidic solution was responsible for this
tendency, though the acidic solution should have been
rapidly buffered in the plasma. Acidic solutions have
been shown to induce CGRP release in the hemisected
rat head preparation [24] and to activate spinal trigemi-
nal neurons when applied to meningeal receptive fields
[25] but there are no data yet with systemic application
of acidic substances.
In previous experiments, in which we used the same
mode of nitroglycerin infusion, we observed an increase
in spinal trigeminal activity that started immediately and
reached significance 25 min after onset of the infusion
Figure 2 Histograms showing mean neuronal activity. Activity
was normalised to the baseline of 10 min periods (a) and of 30 min
periods (b) in the MK-8825 group (grey bars, n = 12) and the vehicle
group (black bars, n = 11); error bars are s.e.m. (c) Mean normalised
activity (+ s.e.m.) of 6 units treated with nitroglycerin (GTN) alone for
two hours. Significant differences in activity compared to the base-
line periods (0–30 min) are indicated by a star and compared to pe-
riods after vehicle/MK-8825 infusion by #; repeated measures ANOVA
and LSD post hoc test (a, b) or WILCOXON (c).
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with a longer observation time, since in the previous
study the activity was observed only for one hour. It
should be mentioned that the nitroglycerin effect is ra-
ther variable between different neurons suggesting that
only a fraction of central neurons is readily under the
control of NO. Within the first hour of nitroglycerin in-
fusion the activity increased significantly in the whole
sample of experiments but the increase did not outlast
the second hour of infusion.
Nitroglycerin in clinically relevant concentrations has
been shown to cause vasorelaxation not necessarily
dependent of NO production, rather by direct activation
of the soluble guanylate cyclase (sGC) dependent intra-
cellular pathway [26,27]. Since vasorelaxation induced
by nitroglycerin can be independent of CGRP release, it
is not surprising that CGRP receptor inhibitors like tel-
cagepant are not effective in inhibiting nitroglycerin in-
duced vasodilation in humans [17]. We assume that the
observed transient increase in activity of spinal trigemi-
nal neurons is due to direct sGC activation. Nitrogly-
cerin, though at a considerably higher systemic dose
(10 mg/kg) as in the present study, has been shown to
activate the transcription factor NF-κB [28] and the cal-
modulin dependent protein kinase II alpha (CamKIIα)
[29] in the rat spinal trigeminal nucleus, which could ex-
plain transcriptional effects causing long-term neuronal
changes. Therefore it seems likely that nitroglycerin and
NO donors cause transient but also transcriptional ef-
fects with a delayed onset and long duration. The upreg-
ulation of CGRP and nNOS immunoreactivity in rat
primary trigeminal afferents six hours after onset of a
nitroglycerin infusion at the same dose as in the present
study [30] and the increase in NOS-positive second
order neurons, which continued during many hours
[31,32], are certainly based on long-term transcriptional
effects. Glutamate receptors in the spinal trigeminal
nucleus seem to be involved in NO-sGC signalling in
regard of both immediate neuronal effects [33] and tran-
scriptional effects, which could be attenuated by the un-
specific glutamate receptor inhibitor kynurenic acid [34].
Transient receptor potential channels type A1 (TRPA1)
have been found to be expressed in peptidergic trigeminal
afferents [35,36] and to cause CGRP release followed by
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onmental stimuli [37]. There is also evidence from recent
experiments in our laboratory that NO species can induce
CGRP release from meningeal afferents via activation of
TRPA1 receptor channels, indicating that this pathway may
come into account to trigger migraine [38]. This issue
should be paid attention to, since TRPA1 can also be
activated by volatile anaesthetics [39]. Therefore it was
important in our experiments to hold the anaesthesia
at a constant level to warrant reproducibility of the
measurements.
Effects of the CGRP receptor inhibitor MK-8825
MK-8825 is related to the compound MK-3207, a CGRP
receptor antagonist with high affinity to human but re-
duced affinity to rat CGRP receptors. MK-8825 has
similar potency as MK-3207, but has a much higher un-
bound fraction in rat plasma. MK-3207 shows inhibition
of capsaicin-induced dermal vasodilatation in rhesus
monkey [40], and in an adaptive dose-ranging trial
MK-3207 demonstrated a positive response on the pri-
mary 2-hour pain freedom endpoint and the secondary
endpoint of 2-hour pain relief in migraine [41]. Both
MK-3207 and MK-8825 are structurally distinct from
telcagepant.
After pre-treatment with MK-8825 the infusion of
nitroglycerin was not followed by the typical slow in-
crease in neuronal activity. There was rather a tendency
towards lowering of activity in the whole sample of ex-
periments, and this decrease was finally significant in
the last 90 min of recording. We conclude that this ef-
fect was due to the inhibition of CGRP receptors by
MK-8825 and that CGRP receptors may be necessary for
the action of nitroglycerin to generate neuronal activity.
Time-dependent differential effects of nitroglycerin, as
discussed above, could explain the discrepancies be-
tween studies using 5-HT1B/D receptor agonists (trip-
tans) to modulate nitroglycerin actions. It has been
reported that the increase in nNOS immunoreactivity in
the rat spinal trigeminal nucleus observed one hour after
10 mg/kg i.v. nitroglycerin was inhibited by sumatriptan
administered shortly before the nitroglycerin infusion
[42]. However, in a parallel study with the same systemic
(s.c.) nitroglycerin dose and a similar dose of sumatrip-
tan, no inhibition of the increased nNOS expression was
found four hours after nitroglycerin [43]. In mice suma-
triptan reduced allodynia induced by nitroglycerin, and
in cats iontophoretically administered eletriptan normal-
ised the elevated discharge rate of spinal trigeminal neu-
rons after nitroglycerin [44], both acute experiments.
Thus it seems that the fast (within one hour) appearing
neuronal effects of nitroglycerin can be attenuated by
blocking CGRP release or CGRP receptors, while later
this is no longer possible. From this we can furtherconclude that the fast neuronal effects of nitroglycerin
depend on the presence of CGRP, while for the long-
lasting effects probably based on gene transcription this
is doubtful.
Clinical implications
The slow increase in spinal trigeminal activity induced
by nitrovasodilators [23] is paralleled by clinical experi-
ments in healthy persons and patients suffering from
primary headaches, in which infusion of nitroglycerin
caused delayed headaches [12–14]. The data of the
present study suggest that inhibition of CGRP receptors
could also be effective in preventing experimental head-
aches. In a cross-over study in patients suffering from
migraine without aura, in which 13 patients received
either olcegepant or placebo after a 20 min infusion of
nitroglycerin, migraine developed in 7 patients after
olcegepant and in 9 patients after placebo, and the head-
ache scores were similar [45]. The authors concluded
that a preventive effect of olcegepant for nitroglycerin-
induced migraine pain could not been confirmed. The
discrepancy between this study and our experimental
data, apart from species differences, may result from dif-
fering preconditions between the two study designs. In
our study MK-8825 was infused 60 min prior to the con-
tinuous nitroglycerin infusion, whereas in the clinical
experiments of the above study [45] olcegepant was in-
fused after nitroglycerin. In our study the increase in ac-
tivity occurred in the first hour and was transient,
whereas the delayed headache attacks in the clinical
study occurred after several hours. It seems likely that
the increase in activity induced by nitroglycerin is a
result of the presumed fast effects discussed above,
whereas the delayed headaches belong to the long-term
events based on gene transcription. Further experiments
should clarify if pre-administration of a CGRP receptor
inhibitor can also prevent the late events induced by
nitroglycerin.
The second question is related to the site of action of
CGRP. From animal experiments we know that CGRP
applied on rat dura mater is not activating meningeal af-
ferents [46]. Thus, if headache is induced by CGRP, it is
most likely a central effect. Assuming that the effects of
MK-8825 and olcegepant in meningeal antinociception
and migraine therapy, respectively, may result from in-
hibition of central CGRP receptors, the effects depend
essentially from the degree of blood brain penetration of
both substances. The question to which extent CGRP re-
ceptor antagonists need to target central CGRP recep-
tors for a therapeutic action is controversely discussed
[47–49]. Animal experiments provide evidence for the
involvement of central CGRP receptors to effectively
inhibit spinal trigeminal activity [50]. Olcegepant is
thought to penetrate the blood brain barrier (BBB) poorly,
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arteries in the study of Tvedskov et al. [45] but for
MK-8825 such data are not available. The issue could pos-
sibly be solved by using CGRP(8–37) as a CGRP receptor
antagonist, which as a peptide should not pass the BBB.Mechanism of CGRP receptor inhibition
If CGRP is required for the fast nociceptive processes in-
duced by nitroglycerin but not for the delayed head-
aches, what is then the mechanism of CGRP receptor
inhibition preventing nitroglycerin-induced increase in
spinal trigeminal activity? CGRP is likely to operate as
co-transmitter in the spinal trigeminal nucleus [51] and
may be particularly important for initiation of central
sensitisation [52]. In animals hypersensitive to CGRP
due to over-expression of the CGRP receptor protein
RAMP1, CGRP has been found to induce mechanical
allodynia [53], most likely a central effect. Neuronal
structures on the level of the first synapse are certainly
central terminals of primary afferents, since CGRP re-
ceptor expression has been found in superficial laminae
but not in second order neurons in the spinal trigeminal
nucleus [54]. Fast sGC-induced processes, as discussed
above, may facilitate nociceptive transmission. The de-
layed transcriptional processes induced by nitroglycerin
include probably the upregulation of NO-producing
neurons [31]. NO released by these neurons may operate
as retrograde transmitter facilitating neurotransmitter
release from primary trigeminal terminals, similar to
neurons in the spinal dorsal horn, for which an analog
function has been postulated [55]. Central sensitisation
accompanying migraine attacks, typically diagnosed by
cutaneous allodynia of trigeminal areas, may be the re-
sult of such long-term changes [56,57]. Triptans are no
longer fully effective for migraine therapy after central
sensitisation has developed [58].
The established role of CGRP as a key mediator in mi-
graine is underlined by a recent report on elevated
CGRP plasma levels during the interictal phases in
chronic migraine [59]. In this increasingly prevalent
disease a preventive therapy targeting CGRP may be
even more important, particularly if the pain is refrac-
tory to conventional therapies. Thus it is encouraging
that, among others, several approaches to block CGRP
or CGRP receptors are in an experimental state, in-
cluding antibodies and mirror-image RNAs (so-called
Spiegelmers) binding to CGRP or CGRP receptors as
well as new CGRP receptor antagonists like those
discussed in the present paper [60–62]. To guide these
developments, a better understanding of the events
linked to CGRP release and to CGRP actions is desir-
able, which is the intention of the present and further
preclinical studies.Conclusions
In the present experiments inhibition of CGRP recep-
tors prevented the increase in spinal trigeminal activity
induced by infusion of nitroglycerin, later followed by
a decrease in activity below baseline. We assume that
CGRP receptor inhibition operates preferably in the
spinal trigeminal nucleus to block neuronal activity
induced by activation of intracellular NO receptors
(soluble guanylate cyclase) at an early state. Assuming
that similar mechanisms are involved in the develop-
ment of spontaneous headache attacks, CGRP receptor
inhibition may be also preventive in migraine.
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